
Clinical Trials
Enrolling trials: Fred Hutchinson Cancer Center at Overlake
Contact: Luat Le |lle@seattlecca.org | 206-606-4191
Protocol name and PI | Indication/Eligibility |
|
Hockenbery +1 year Study PI: David Hockenbery Local PI: Jason Comer | Treatment naïve, colorectal cancer, any stage -no ab, probiotic use | Features of Gut Microbiome Promoting Colorectal Cancers in Different Risk Groups -Biorepository: stool sample collection study |
EA2186 GIANT PI: David Zhen Local PI: Jason Comer | Metastatic pancreatic cancer -70 years or older | A Randomized Phase II Study of Gemcitabine and NabPaclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT) |
ColoCare, Consortium PI: William Grady, Christopher Li, Fred Hutch | Colorectal Cancer, any stage -allows ab, probiotic use -diagnosed w/in past 12 months -intact primary | Discovery and verification of novel biomarkers of colorectal cancer recurrence -Biorepository: blood sample collection |
Updated 10/07/2022
GU CANCER ENROLLING TRIALS
Protocol name and PI | Indication/Eligibility | Protocol title |
PROMISE PI: Heather Cheng, SLU | Any prostate cancer | PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness -Free color genomics testing |
S1802 PI: Heather Cheng | Metastatic Prostate Cancer -no more than 28 weeks of SST, brain mets ineligible, requires urology consult | Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer |
CASPAR A031902 Consortium PI: Prakash Varadarajan Local PI: Jason Comer” | Metastatic Castration Resistant Prostate Cancer -archival tissue available, no prior enzalutamide | A Phase III Trial of Enzulatamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer |
Updated 10/07/2022
MALIGNANT HEME ENROLLING TRIALS
Protocol name and PI | Indication/Eligibility | Protocol title |
S1925 EVOLVE Consortium PI: Mazyar Shadman Local PI: Jason Comer | Newly diagnosed asymptomatic high risk patients with chronic lymphocytic lymphoma/small lymphocytic lymphoma -diagnosed w/in past 12 months | Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study |
S1918 Consortium PI: Paul Martin Local PI: Jason Comer | Older patients with DLBCL, transformed lymphoma, high grade lymphoma w MYC and BCL2 and/or BCL6 rearrangements -75 years or older | A Phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed diffuse large B cell lymphoma, Grade IIIb Follicular Lymphoma, transformed lymphoma, and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements |
Updated 10/07/2022
LUNG CANCER ENROLLING TRIALS
Protocol name and PI | Indication/Eligibility | Protocol title |
EA5181 Consortium PI: Dan Moore Local PI: Jason Comer | First line: Unresectable stage III (A/B/C) NSCLC or nodal recurrence after surgery for early stage NSCLC -PFTs required for screening | Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC Chemo options: -Cisplatin/Etoposide -Pemetrexed/Cisplatin (non-squamous histology only) -Paclitaxel/Carboplatin |
BREAST CANCER ENROLLING TRIALS
Protocol name and PI | Indication/Eligibility | Protocol title |
Breast Repository Study PI: Eileen Consorti | Any Overlake Breast cancer patients or breast patients interested in the study | Breast Repository Study at Overlake |
Updated 10/07/2022